Skip to main content

Peptic Ulcer- Clinical Manifestations, Presenting Symptoms, Alarming features and Investigating Tests!

 PEPTIC ULCER

Clinical Manifestations:

  • Upper abdominal pain; occurring 1-3hour after meals and relieved by food or antacids in the classic symptom of peptic-ulcer disease.
  • Anorexia
  • Weight loss
  • Nausea
  • Vomiting
  • Heartburn
  • Hemorrhage
  • Chronic-iron deficiency anemia
  • Pyloric stenosis
  • Perforations
  • In the elderly, the presentation is more likely to be silent and gastro-intestinal bleeding may be the first clinical sign of disease.

Patient Assessment:

Presenting symptoms of dyspepsia require careful assessment to judge the risk of serious disease or to provide appropriate symptomatic treatment.

     1.Reflux-like dyspepsia:

  • Heartburn plus dyspepsia
  • Acid regurgitation plus dyspepsia

      2. Ulcer-like dyspepsia:

  •  Localized epigastric pain.
  • Pain when hungry
  • Pain relieved by food.
  • Pain relieved by antacids or acid-reducing drugs.
  • Pain that wakens the patient from sleep
  • Pain with remission and relapse

     3. Dysmotility-like Dyspepsia:

  • Upper abdominal discomfort (pain not dominant)
  • Early satiety
  • Postprandial fullness
  • Nausea
  • Vomiting
  • Bloating in the upper abdomen (No visible distention)
  • Upper abdominal discomfort often aggravated by food

      4. Unspecified dyspepsia


Drugs Causing Dyspepsia:

  1. Antibiotics
  2. Bisphosphonates
  3. Calcium Channel Blockers
  4. Corticosteroids
  5. Drugs with Anti-muscarinic effects e.g: Tricyclic Antidepressants
  6. Iron
  7. Nitrates
  8. NSAIDs including Aspirin.
  9. Potassium Chloride
  10. Theophylline

Alarming Features:

  • Dysphagia (medical term for difficulty in swallowing)
  • Pain on swallowing
  • Unintentional weight loss
  • Gastro-intestinal bleeding or Anemia
  • Persistent vomiting
  • On NSAIDs or Warfarin

Investigations:

1. Endoscopy: 

  • Endoscopy is generally the investigation of choice for diagnosing peptic ulcer. The procedure is sensitive, specific and safe. However, it is also invasive and expensive.
  • Endoscopic investigations should be undertaken in patients with alarming features and in those over 55 years who present with unexplained or persistent symptoms of dyspepsia.
  • Biopsies may be taken to exclude malignancy and uncommon lesions such as Crohn's Disease.
  • Patients with upper gastro-intestinal bleeding have traditionally undergone endoscopy.
  • Most patients do not require endoscopy and in those at low risk, endoscopy and admission to hospital can be avoided by application of Scoring system. The most widely used is the ROCKALL RISK Scoring System (which includes endoscopic findings to predict poor outcome).

2.Radiology:

  • Double-contrast Barium Radiography should detect 80% of peptic ulcers.
  • A Gastrograffin meal is used to diagnose peptic perforation in patients presenting with an acute abdomen, if a plain abdominal X-ray is not diagnostic.

3. H.Pylori Detection:

There are several methods of detecting H.Pylori infection. They include non-invasive tests such as;

  • Serological tests 
  • Urea Breath Tests
  • Stool Antigen Tests
  • Invasive Tests

  1. Serological tests: Is used to detect antibodies, (anti-H.Pylori IgG antibodies) but are not able to distinguish between active or previous exposure to infection.
  2. Urea Breath Tests: have a sensitivity and specificity over 90% and are accurate for both initial diagnosis and confirmation of eradication. The breath test is based on the principle of urease activity in stomach of infected individuals hydrolyses urea to form ammonia and Carbon dioxide. The test contains carbon-labelled urea which, when hydrolyzed results in production of labelled Carbon dioxide which appears in the breath test. The breath test is preferable and more convenient.
  3. Stool Antigen Test: uses an enzyme immunoassay to detect H.Pylori antigen i stool. This test has a sensitivity and specificity of over 90% and can be used in initial diagnosis and also to confirm eradication.
  4. Invasive tests: require gastric antral biopsies; include urease tests, histology, and culture. Of these, the biopsy urease test is widely used. Agar-based biopsy urease tests are designed to be read at 24hour. Strip-based biopsy urease tests are to be read at 2 hours.
  5. The fecal occult Blood test: is not specific for or sensitive to detection of NSAID-induced gastric damage. A full blood count may provide evidence of blood loss from peptic ulcer.

Labels:

Comments

Post a Comment

Popular posts from this blog

Diabetes Mellitus: Types!

TYPES OF DIABETES MELLITUS 1. TYPE1 DM Type 1 DM is usually diagnosed before age 30 years, but it can develop at any age. T1DM is an autoimmune disease in which insulin producing B-cells are destroyed. The presence of Human Leucocyte Antigens (HLAs ) is associated with the development of T1DM. In addition, these individuals often develop Islet cell antibodies , Insulin Autoantibodies or Glutamic Acid decarboxylase autoantibodies . At the time of development of diagnosis of T1DM, it is usually believed that most of the patients have 80-90%loss of beta cells. The remaining beta cells function at the diagnosis creates a " HONEYMOON PERIOD" during which the blood glucose levels are easier to control, and smaller amounts of insulin are required. after this, the remaining beta cells function is completely lost, and the patients become completely deficient of insulin and hence require exogenous insulin.  2. TYPE1.5 DM:  Also referred as Latent autoimmune diabetes in Adults (LAD)
Post a Comment
Read more

Diabetes Mellitus: Pharmacotherapy- Gliptins and a-Glycoside Inhibitors!

  PHARMACOTHERAPY:  Medications classifications include:  Sulfonyl Urea's Nonsylfonylurea Secretagogues (a-Glinides) Biguanides Thiazolidinediones a-Glucosidase Inhibitors Dipeptidyl Peptidase-4 Inhibitors (Gliptins) Sodium-glucose co-transporter (SGLT) Inhibitors  Central-Acting Dopamine Agonists Bile Acid Sequestrants Insulin therapy 5. a-GLUCOSIDASE INHIBITORS Acarbose and Miglitol are a-glucosidase inhibitors currently approved in the United States. Mechanism of Action: An enzyme that is along the brush border of the intestine cells called a-glucosidase; breaks down the complex carbohydrates into simple sugars, resulting in absorption. The a-glucosidase inhibitors work by delaying the absorption of carbohydrates from the intestinal tract, which reduces the rise in postprandial glucose levels. Therapy: As a monotherapy , a-glucosidase inhibitors primarily reduce post-prandial glucose excursions.  Clinical Use: FPG concentrations have been decreased by 40-50mg/dL and A1c level
Post a Comment
Read more

GASTRO-ESOPHAGEAL REFLUX DISEASE (GERD)!

MANAGEMENT OF GASTRO-ESOPHAGEAL REFLUX DISEASE  "GERD refers to the endoscopically determined esophagitis or endoscopy-negative reflux disease" . "GERD is the term used to describe any symptomatic clinical condition or histopathological alteration resulting from episodes of reflux of acid, pepsin and occasionally, bile into the esophagus from the stomach". Patients with uninvestigated "reflux-like" symptoms should be managed as patients with uninvestigated dyspepsia. There is currently no evidence that H.pylori should be investigated in patients with GERD. Symptoms: Heartburn is the characteristic symptom of GERD. Acid regurgitation Dysphagia Belching Upper abdominal discomfort Bloating and postprandial fullness Chest pain Hoarseness Cough Complications include: Esophageal ulceration Formation of specialized columnar-lined esophagus at the gastro-esophageal junction known as Barretts Esophagus . Mechanism of Acid Reflux: The mechanism of acid reflux is mu
Post a Comment
Read more